A Randomized Controlled Phase II Trial With Intradermal IMO-2125 in Pathological Tumor Stage (p) T3-4 cN0M0 Melanoma
Condition: Malignant Melanoma Interventions: Drug: Tilsotolimod; Drug: Saline (0.9% sodium chloride) Sponsors: A.J.M. van den Eertwegh; Idera Pharmaceuticals, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials